Recruiting

AccuMeasure

Sponsor:

Centre hospitalier de l'Université de Montréal (CHUM)

Code:

NCT07770425

Conditions

Polyp of Colon

Crohn Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The goal of this prospective observational study is to assess the accuracy and reliability of laser readings obtained through AccuMeasure, in comparison to other measurements performed by gastroenterologists. AccuMeasure is a novel technology, that has emerged as a promising tool for measuring polyps and lesions during colonoscopies. The system employs laser-based measurements, enabling precise determination of lesion size, depth, and extent. The main hypotheses this study aims to evaluate are:

  • AccuMeasure technology, with its precise laser measurements, will demonstrate superior accuracy and reliability in assessing lesion size of pathologies encountered during endoscopies, when compared to other endoscopic scoring methods.
  • AccuMeasure measurements will show strong construct validity by correlating significantly with endoscopic subscores, symptomatic remission (CD PRO2 <8, partial mayo score), and fecal calprotectin values.

Conditions

Polyp of Colon

Crohn Disease

Study ID

NCT07770425

Start date

May 9, 2025

Status verified date

Nov, 2025

Completion date

Nov, 2027

Anticipated

Primary completion date

May, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult patients (18 years and older)
  • Patients undergoing gastrointestinal endoscopy procedures

Exclusion Criteria:

  • Minors: Patients under 18 years of age.
  • Patients who do not provide informed consent.
  • Patients undergoing endoscopy on an emergency basis (defined as urgent diagnostic or therapeutic endoscopy performed on the gastrointestinal (GI) tract to address potentially life-threatening conditions or severe symptoms that require immediate medical attention).
  • An American Society of Anesthesiologists (ASA) physical status classification greater than 3.

Study Design

Enrollment

3000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Validity of AccuMeasure when measuring ulcer size in patients with Crohn's disease or ulcerative colitis [ Time Frame: During the endoscopy ]
  • Reliability of AccuMeasure when measuring ulcer size in patients with Crohn's disease or ulcerative colitis [ Time Frame: During the endoscopy ]
  • Correlation between AccuMeasure and Endoscopic Disease Activity when measuring ulcer size in patients with Crohn's disease or ulcerative colitis [ Time Frame: During the endoscopy ]
  • Relative Inaccuracy of Visual Estimation Compared to AccuMeasure (Laser-Based Device) for Ulcer Size in Patients with Crohn's Disease or Ulcerative Colitis [ Time Frame: During the endoscopy ]
  • Relative Inaccuracy of Snare-Based Measurement Compared to AccuMeasure for Ulcer Size in Patients with Crohn's Disease or Ulcerative Colitis [ Time Frame: During the endoscopy ]
  • Relative Inaccuracy of Forceps-Based Measurement Compared to AccuMeasure for Ulcer Size Measurement in Patients with Crohn's Disease or Ulcerative Colitis [ Time Frame: During the endoscopy ]
  • Relative Inaccuracy of AI-Based Measurement Compared to AccuMeasure for Ulcer Size Measurement in Patients with Crohn's Disease or Ulcerative Colitis [ Time Frame: During the endoscopy ]

Central Contacts and Locations

Locations

Centre Hospitalier de l'Université de Montréal

Recruiting

Montreal, Quebec, Canada

Contacts

Samira Hanin

514-890-8000samira.hanin.chum@ssss.gouv.qc.ca

Principal Investigator:

Daniel von Renteln, MD, PhD

More Information

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Last update posted

Aug 18, 2026

Last verified

Nov, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Centre hospitalier de l'Université de Montréal (CHUM) on 2026-08-18.